Propanc Biopharma (PPCB) Net Equity Issued and Repurchased (2011 - 2025)
Propanc Biopharma (PPCB) posted quarterly Net Equity Issued and Repurchased of $3.3 million for Q3 2025, up 27578.15% quarter-over-quarter from $11975.0 in Q2 2024.
Propanc Biopharma (PPCB) Net Equity Issued and Repurchased (2011 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Net Equity Issued and Repurchased for 7 consecutive years, with $3.3 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $3.3 million; the TTM figure through Dec 2025 stood at $3.5 million (changed N/A YoY), while the FY2024 annual figure was $23057.0, down 6.69% from the prior year.
- Net Equity Issued and Repurchased rose to $3.3 million in Q3 2025 per PPCB's latest filing, from $11975.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $3.3 million in Q3 2025 and bottomed at $11975.0 in Q2 2024.
- Historically, Net Equity Issued and Repurchased has averaged $566680.9 across 4 years, with a median of $99285.0 in 2022.
- On a YoY basis, Net Equity Issued and Repurchased climbed as much as 827.48% in 2023 and fell as far as 827.48% in 2023.
- Propanc Biopharma's Net Equity Issued and Repurchased stood at $24711.0 in 2022, then soared by 272.53% to $92057.0 in 2023, then plunged by 86.99% to $11975.0 in 2024, then jumped by 27578.15% to $3.3 million in 2025.
- Business Quant data shows PPCB's Net Equity Issued and Repurchased at $3.3 million in Q3 2025, $11975.0 in Q2 2024, and $195090.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3.31 Mn |
| Sep 30, 2025 | 3.31 Mn |
| Jun 30, 2024 | 11,975.00 |
| Jun 30, 2024 | 11,975.00 |
| Mar 31, 2024 | 195,090.00 |
| Mar 31, 2024 | 195,090.00 |
| Dec 31, 2023 | 92,057.00 |
| Dec 31, 2023 | 92,057.00 |
| Sep 30, 2023 | 229,190.00 |
| Sep 30, 2023 | 229,190.00 |
| Sep 30, 2022 | 24,711.00 |
| Sep 30, 2022 | 24,711.00 |
| Jun 30, 2022 | 99,285.00 |
| Jun 30, 2022 | 99,285.00 |
| Jun 30, 2019 | 68,401.00 |
| Jun 30, 2019 | 68,401.00 |
| Mar 31, 2019 | 100,000.00 |
| Mar 31, 2019 | 100,000.00 |
| Jun 30, 2012 | 17,629.00 |
| Jun 30, 2012 | 17,629.00 |